Skip to main content
SpringerLink
Log in

In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The stability and excretion of [14C]-gadodiamide (GdDTPA-BMA) was studied in male rats after i.v. injection of 0.3 mmol/kg [14C]-GdDTPA-BMA (Gd-diethylenetriaminepentaacetic-acid-bis-methylamide) formulated as gadodiamide injection (OMNISCAN®, Nycomed Imaging AS. Oslo, Norway). Samples of blood and urine obtained within 60 min and 6 h postdosing, respectively, were analyzed for radiolabeled compounds. Analysis of GdDTPA-BMA in high and low molecular weight fractions of serum indicated no protein binding. HPLC analyses of urine samples obtained 0–2 h, 2–4 h and 4–6 h after injection revealed no detectable amounts of biotransformation products of GdDTPA-BMA. Serum samples obtained 30 min and 60 min after injection contained 9–13 μM of an unidentified compound which had a retention time different from all conceivable metabolites of gadodiamide. A similar concentration of this unknown compound was found in spiked predose serum samples. The total amount of the unknown compound in serum was less than 1% of the injected dose of [14C]-gadodiamide injection. It is concluded that gadodiamide, when administered i.v. as gadodiamide injection at a dosage of 0.3 mmol/kg, is stable in vivo and that the very major part of the dose (> 99%) is excreted in urine as an unchanged complex.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harpur S.E., Worah D., Hals P-A., Holtz E., Furuhama K., Nomura H. (1993): Preclinical assessment of pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest. Radiol., 28 (Suppl. 1), S28-S43.

    Article  CAS  PubMed  Google Scholar 

  2. Øksendal A.N., Hals P-A. (1993): Biodistribution and toxicity of MR imaging contrast media. J. Magn. Reson. Imaging, 3, 157–165.

    Article  PubMed  Google Scholar 

  3. Bamhart J.L., Kuhnert N., Bakan D.A., Berk R.N. (1987): Biodistribution of GdCl3 and Gd-DTPA and their influence on proton magnetic relaxation in rat tissues. Magn. Reson. Imaging, 5, 221–231.

    Article  Google Scholar 

  4. Wedeking P., Tweedle M. (1988): Comparison of the biodistribution of153Gd-labeled Gd(DTPA)2−, Gd(DOTA)−, and Gd(acetate)n in mice. Nucl. Med. Biol., 15, 395–402.

    CAS  Google Scholar 

  5. Durbin P.W., Williams M.H., Ge M., Newman R.H., Hamilton J.G. (1956): Metabolism of lanthanons in the rat. Proc. Soc. Exp. Biol. Med., 91, 78–85.

    CAS  PubMed  Google Scholar 

  6. VanWagoner M., O’Toole M., Worah D., Leese P.T., Quay S.C. (1991): A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest. Radiol., 26, 980–986.

    Article  CAS  PubMed  Google Scholar 

  7. Hvattum E., Normann P.T., Jamieson G.C., Lai J-J., Skotland T. (1995): Detection and quantitation of gadolinium-chelates in human serum and urine by high-performance liquid chromatography and post-column derivatization of gadolinium with Arsenazo III. J. Pharmaceut. Biomed. Anal., 13, 927–952.

    Article  CAS  Google Scholar 

  8. Wedeking P., Kumar K., Tweedle M.F. (1992): Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn. Reson. Imaging, 10, 641–648.

    Article  CAS  PubMed  Google Scholar 

  9. Harrison A., Walker C.A., Pereira K.A., et al. (1993): Hepato-biliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-aza-phosphinic and carboxylic acids. Magn. Reson. Imaging, 11, 761–770.

    Article  CAS  PubMed  Google Scholar 

  10. Weinmann H.J., Brasch R.C., Press W.R., Westbey G.E. (1984): Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am. J. Radiol., 142, 619–624.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research and Development, Nycomed Imaging AS, 4220 Torshov, PO Box, N-0401, Oslo, Norway

    P. T. Normann & P. A. Hals

Authors
  1. P. T. Normann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. A. Hals
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Normann, P.T., Hals, P.A. In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging. European Journal of Drug Metabolism and Pharmacokinetics 20, 307–313 (1995). https://doi.org/10.1007/BF03190250

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190250

Keywords

Search

Navigation